Dermatologic Manifestations of Zika Virus

Zika Virus Symptoms and the Associated Exanthema Clinical Trial

— DMZV  

Official title:

Survey of Symptoms and Dermatologic Characterization Associated With Zika Virus

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03229421
• Other study ID #: STU00205325
• Status: Withdrawn
• Start date: July 6, 2017
• Est. completion date: December 31, 2018

Study information

• Verified date: January 2019
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether any diagnostic patterns exist in the symptom presentation of Zika Virus.

Description:

The study has both retrospective and prospective components. The retrospective review includes medical records with laboratory confirmed Zika Virus diagnosis and the prospective component will enroll adults presenting with febrile illness and rash and ask them to complete a survey about their symptoms. Diagnostic testing will be completed to confirm infection source.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 31, 2018
• Est. primary completion date: December 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults aged 18 years and older presenting with febrile illness and rash

Exclusion Criteria:

• Patients aged 17 years or younger

Related Conditions & MeSH terms

• Exanthema
• Zika Virus Infection
• Zika Virus Symptoms and the Associated Exanthema

Intervention

Other:
• Survey
18 question symptom assessment tool including non-identifying demographic information questions.

Locations

Country	Name	City	State
Dominican Republic	Pontificia Universidad Catolica Madre y Maestra, Departamento de Medicina	Santo Domingo	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Northwestern University	Pontificia Universidad Catolica Madre y Maestra

Country where clinical trial is conducted

Dominican Republic, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of days with specific symptoms	Number of days reported experiencing specific symptoms due to Zika Virus infection and and associated characteristics such as location and intensity	20 minutes
Secondary	Frequency measures of initial clinical presentations	Frequency of reported symptoms at initial clinical presentation.	20 minutes